{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:38:02Z","timestamp":1793709482610,"version":"4.6.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":35,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim Corp USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021316","name":"AstraZeneca Pharmaceuticals LP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009155","name":"Otsuka America Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.ajkd.2026.06.017","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:44:48Z","timestamp":1790135088000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Application of Kidney Hierarchical Composite Endpoints in Trials of CKD Progression: Report of a Scientific Workshop Sponsored by the National Kidney Foundation"],"prefix":"10.1053","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2820-9482","authenticated-orcid":false,"given":"Lesley A.","family":"Inker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Chertow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli Collins","family":"Damron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie F.","family":"Furberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samvel B.","family":"Gasparyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig E.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrefna","family":"Gu\u00f0mundsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Jongs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cari","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precious","family":"McCowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Mottl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schloemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Siew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duane","family":"Sunwold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Vock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Willis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila R.","family":"Zelnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1053\/j.ajkd.2026.06.017_bib1","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients With Chronic Kidney Disease (DAPA-CKD)","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.06.017_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1053\/j.ajkd.2026.06.017_bib3","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.06.017_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2026.06.017_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","article-title":"The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities","volume":"33","author":"Pocock","year":"2012","journal-title":"Eur Heart J"},{"issue":"22","key":"10.1053\/j.ajkd.2026.06.017_bib6","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1002\/sim.6987","article-title":"Probabilistic measures of cost-effectiveness","volume":"35","author":"Bebu","year":"2016","journal-title":"Stat Med"},{"issue":"30","key":"10.1053\/j.ajkd.2026.06.017_bib7","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1002\/sim.3923","article-title":"Generalized pairwise comparisons of prioritized outcomes in the two-sample problem","volume":"29","author":"Buyse","year":"2010","journal-title":"Stat Med"},{"issue":"12","key":"10.1053\/j.ajkd.2026.06.017_bib8","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1681\/ASN.0000000000000244","article-title":"Validity and utility of a hierarchical composite end point for clinical trials of kidney disease progression: a review","volume":"34","author":"Little","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2026.06.017_bib9","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1681\/ASN.0000000000000243","article-title":"Development and validation of a new hierarchical composite end point for clinical trials of kidney disease progression","volume":"34","author":"Heerspink","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2026.06.017_bib10","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.ajkd.2026.06.017_bib11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2026.06.017_bib12","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ejhf.2853","article-title":"The win ratio method in heart failure trials: lessons learnt from EMPULSE","volume":"25","author":"Pocock","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.017_bib13","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/j.ajkd.2014.08.017","article-title":"GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials","volume":"64","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.017_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.017_bib15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1053\/j.ajkd.2014.09.006","article-title":"GFR decline as an end point in trials of CKD: a viewpoint from the FDA","volume":"64","author":"Thompson","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ajkd.2026.06.017_bib16","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.ajkd.2026.06.017_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","article-title":"Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA","volume":"75","author":"Thompson","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2026.06.017_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.ajkd.2022.03.011","article-title":"Clinical trial considerations in developing treatments for early stages of common, chronic kidney diseases: a scientific workshop cosponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"80","author":"Inker","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2026.06.017_bib20","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2026.06.017_bib21","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2026.06.017_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2026.06.017_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2021070948","article-title":"Acute treatment effects on GFR in randomized clinical trials of kidney disease progression","volume":"33","author":"Neuen","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2026.06.017_bib24","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.kint.2024.05.024","article-title":"A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection","volume":"106","author":"Heerspink","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2026.06.017_bib25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/biom.13438","article-title":"Biased estimation with shared parameter models in the presence of competing dropout mechanisms","volume":"78","author":"Vonesh","year":"2022","journal-title":"Biometrics"},{"issue":"11","key":"10.1053\/j.ajkd.2026.06.017_bib26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7","article-title":"Combining mortality and longitudinal measures in clinical trials","volume":"18","author":"Finkelstein","year":"1999","journal-title":"Stat Med"},{"issue":"5","key":"10.1053\/j.ajkd.2026.06.017_bib27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s43441-022-00420-1","article-title":"Design and analysis of studies based on hierarchical composite endpoints: insights from the DARE-19 trial","volume":"56","author":"Gasparyan","year":"2022","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"10.1053\/j.ajkd.2026.06.017_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/pst.2251","article-title":"Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes","volume":"22","author":"Dong","year":"2023","journal-title":"Pharm Stat"},{"issue":"14","key":"10.1053\/j.ajkd.2026.06.017_bib29","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1002\/sim.8967","article-title":"Win odds: an adaptation of the win ratio to include ties","volume":"40","author":"Brunner","year":"2021","journal-title":"Stat Med"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.017_bib30","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.kint.2025.09.016","article-title":"Changing paradigms of studies in kidney diseases","volume":"108","author":"Levin","year":"2025","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2026.06.017_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100442","article-title":"Treating early-stage CKD with new medication therapies: results of a CKD patient survey informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases","volume":"4","author":"Damron","year":"2022","journal-title":"Kidney Med"},{"issue":"3","key":"10.1053\/j.ajkd.2026.06.017_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/bimj.70140","article-title":"The univariate distribution of hierarchical composite endpoints and the condorcet non-transitivity paradox","volume":"68","author":"Gasparyan","year":"2026","journal-title":"Biom J"},{"issue":"3","key":"10.1053\/j.ajkd.2026.06.017_bib34","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/biomet\/asw026","article-title":"On the win-ratio statistic in clinical trials with multiple types of event","volume":"103","author":"Oakes","year":"2016","journal-title":"Biometrika"},{"issue":"4","key":"10.1053\/j.ajkd.2026.06.017_bib35","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.kint.2020.07.013","article-title":"International consensus definitions of clinical trial outcomes for kidney failure: 2020","volume":"98","author":"Levin","year":"2020","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2026.06.017_bib36","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1681\/ASN.0000000766","article-title":"Use of eGFR slope thresholds as end point components in a kidney disease progression hierarchical composite end point","volume":"36","author":"Jongs","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"10.1053\/j.ajkd.2026.06.017_bib37","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1161\/CIRCULATIONAHA.123.067786","article-title":"Win Ratio: A seductive but potentially misleading method for evaluating evidence from clinical trials","volume":"149","author":"Butler","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2026.06.017_bib38","article-title":"Interpretational challenges of the win ratio in analyzing hierarchical composite endpoints in chronic kidney disease","author":"Thomsen","year":"2025","journal-title":"arXiv"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.017_bib39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-025-01250-9","article-title":"How hazard ratios can mislead and why it matters in practice","volume":"40","author":"Dumas","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"10.1053\/j.ajkd.2026.06.017_bib40","series-title":"Vyndaquel\/Vyndamax (tafamidis). Prescribing information","year":"2023"},{"issue":"6","key":"10.1053\/j.ajkd.2026.06.017_bib41","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.kint.2025.03.011","article-title":"Contribution of the glomerular filtration rate slope to the kidney hierarchical composite endpoint","volume":"107","author":"Little","year":"2025","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2026.06.017_bib42","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.0000000994","article-title":"A hierarchical composite endpoint for chronic kidney disease progression in patients with focal segmental glomerulosclerosis","author":"Heerspink","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10433","key":"10.1053\/j.ajkd.2026.06.017_bib43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(23)02843-X","article-title":"Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort","volume":"403","author":"Wong","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ajkd.2026.06.017_bib44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2215\/CJN.13101019","article-title":"Identifying outcomes important to patients with glomerular disease and their caregivers","volume":"15","author":"Carter","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2026.06.017_bib45","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2024.07.009","article-title":"KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD)","volume":"107","year":"2025","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2026.06.017_bib47","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s13063-017-2298-4","article-title":"Standardised Outcomes in Nephrology-Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease","volume":"18","author":"Cho","year":"2017","journal-title":"Trials"},{"issue":"9","key":"10.1053\/j.ajkd.2026.06.017_bib48","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1007\/s00134-024-07560-y","article-title":"Recommendations for clinical trial design in acute kidney injury from the 31st acute disease quality initiative consensus conference: a consensus statement","volume":"50","author":"Zarbock","year":"2024","journal-title":"Intensive Care Med"},{"key":"10.1053\/j.ajkd.2026.06.017_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2024.154767","volume":"82","author":"Zampieri","year":"2024","journal-title":"J Crit Care"},{"key":"10.1053\/j.ajkd.2026.06.017_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2022.154113","article-title":"Hierarchical endpoint analysis using win ratio in critical care: an exploration using the balanced solutions in intensive care study (BaSICS)","volume":"71","author":"Zampieri","year":"2022","journal-title":"J Crit Care"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626011236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626011236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:16:11Z","timestamp":1793708171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626011236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":47,"alternative-id":["S0272638626011236"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.06.017","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of Kidney Hierarchical Composite Endpoints in Trials of CKD Progression: Report of a Scientific Workshop Sponsored by the National Kidney Foundation","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2026.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}